YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
As February begins, the U.S. stock market is showing strength, with major indexes like the Dow Jones and S&P 500 posting significant gains. In this context of rising indices, investors often look for opportunities that may offer growth pot…
Company Logo The Acute Respiratory Distress Syndrome (ARDS) market is projected to grow from $1.32 billion in 2024 to $2.53 billion by 2033, registering a CAGR of 7.51% from 2025 to 2033. Key factors driving this growth include the rise in…
Key Insights Significant insider control over Silence Therapeutics implies vested interests in company growth 53% of the business is held by the top 4 shareholders Institutions own 24% of Silence Therapeutics A look at the shareholders of…
Silence Therapeutics PLC Sponsored ADR (SLN) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most pow…
While "the trend is your friend" when it comes to short-term investing or trading, timing entries into the trend is a key determinant of success. And increasing the odds of success by making sure the sustainability of a trend isn't easy. O…
Looking at Silence Therapeutics plc's (NASDAQ:SLN ) insider transactions over the last year, we can see that insiders were net buyers. That is, there were more number of shares purchased by insiders than there were sold. While we would nev…
Silence Therapeutics PLC Sponsored ADR (SLN) closed the last trading session at $14.05, gaining 43.4% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts a…
Curtis Rambaran, MD, promoted to Chief Medical Officer Marie Wikström Lindholm, PhD, promoted to Chief Scientific Officer LONDON, December 01, 2023--(BUSINESS WIRE)--Silence Therapeutics plc, Nasdaq: SLN ("Silence" or the "Company"), an ex…
Silence Therapeutics plc (NASDAQ:SLN) shares have had a really impressive month, gaining 65% after a shaky period beforehand. Unfortunately, the gains of the last month did little to right the losses of the last year with the stock still d…
Silence Therapeutics PLC Sponsored ADR (SLN) closed the last trading session at $9.10, gaining 27.6% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts ar…
SLN124 phase 1/2 study in polycythemia vera progressing well – data expected in mid-2024 Zerlasiran multiple dose study in patients with high Lp(a) and stable ASCVD showed significant and durable reductions in Lp(a) of up to 99% Fully enro…
LONDON, November 08, 2023--(BUSINESS WIRE)--Silence Therapeutics plc, Nasdaq: SLN ("Silence" or the "Company"), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through prec…
Zerlasiran showed very significant and durable reductions in lipoprotein(a) of up to 99% Lp(a) levels remained around 90% lower than baseline at study endpoint LONDON, November 01, 2023--(BUSINESS WIRE)--Silence Therapeutics plc, Nasdaq: S…
LONDON, September 26, 2023--(BUSINESS WIRE)--Silence Therapeutics plc, Nasdaq: SLN ("Silence" or the "Company"), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through pre…
LONDON, September 06, 2023--(BUSINESS WIRE)--Silence Therapeutics plc, Nasdaq: SLN ("Silence" or the "Company"), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through pre…
LONDON, August 16, 2023--(BUSINESS WIRE)--Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precis…
LONDON, July 11, 2023--(BUSINESS WIRE)--Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), an experienced and innovative biotechnology company committed to transforming peoples’ lives by silencing diseases through precisio…
LONDON, May 31, 2023--(BUSINESS WIRE)--Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision…
LONDON, May 16, 2023--(BUSINESS WIRE)--Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision…
LONDON, May 04, 2023--(BUSINESS WIRE)--Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision…
LONDON, May 01, 2023--(BUSINESS WIRE)--Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision…
LONDON, April 25, 2023--(BUSINESS WIRE)--Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precisi…
– Study provides therapeutic rationale for SLN124, Silence’s clinical candidate for polycythemia vera and other hematological disorders LONDON, April 04, 2023--(BUSINESS WIRE)--Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Compa…
LONDON, March 29, 2023--(BUSINESS WIRE)--Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precisi…
Dr. Romano will succeed Dr. Giles Campion, CMO and Head of R&D, following his retirement by year-end LONDON, March 28, 2023--(BUSINESS WIRE)--Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), an experienced and innovative…
Deal gives Silence exclusive worldwide rights to two siRNA complement assets LONDON, March 28, 2023--(BUSINESS WIRE)--Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), an experienced and innovative biotechnology company c…
Silence Therapeutics plc (NASDAQ:SLN) Q4 2022 Earnings Call Transcript March 15, 2023 Operator: Good day and thank you for standing by. Welcome to the Silence Therapeutics 2022 Annual Results Conference Call and Webcast. Please be advised…
Company to host fourth quarter conference call and webcast today at 8 a.m. EDT / 12 p.m. GMT LONDON, March 15, 2023--(BUSINESS WIRE)--Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), an experienced and innovative biotech…
Silence Therapeutics PLC Sponsored ADR (SLN) shares soared 9.3% in the last trading session to close at $11.16. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's…
LONDON, March 02, 2023--(BUSINESS WIRE)--Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precisi…
LONDON, February 08, 2023--(BUSINESS WIRE)--Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through prec…
LONDON, February 06, 2023--(BUSINESS WIRE)--Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through prec…
For Immediate Release Chicago, IL – January 19, 2023 – Today, Zacks Equity Research discusses Dyne Therapeutics DYN, Silence Therapeutics SLN, Alaunos Therapeutics TCRT, Assertio Holdings ASRT and Acer Therapeutics ACER. Industry: Medical…
Innovation is expected to be the key to growth of the drug/biotech sector in 2023. The drug/biotech sector has been witnessing developments in pipeline areas like rare diseases, gene therapy and editing, and mRNA-based drugs and vaccines.…
LONDON, January 12, 2023--(BUSINESS WIRE)--Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through preci…
Silence Therapeutics PLC Sponsored ADR (SLN) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices --…